Affordable Access

deepdyve-link
Publisher Website

Unilateral radiotherapy treatment for p16/human papillomavirus-positive squamous cell carcinoma of unknown primary in the head and neck.

Authors
  • Tiong, Albert1
  • Rischin, Danny2, 3
  • Young, Richard J4
  • Herschtal, Alan5
  • Solomon, Ben2, 3
  • D'Costa, Ieta1
  • Fua, Tsien1
  • Liu, Chen1
  • Coleman, Andrew1
  • Kleid, Stephen6
  • Dixon, Benjamin J6, 7
  • Corry, June3, 8
  • 1 Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 2 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 3 University of Melbourne, Parkville, Victoria, Australia. , (Australia)
  • 4 Molecular Therapeutics and Biomarkers Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 5 Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 6 Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 7 Department of Surgery, University of Melbourne, St. Vincent's Hospital, Fitzroy, Victoria, Australia. , (Australia)
  • 8 GenesisCare Radiation Oncology Centre, St Vincent's Hospital, Fitzroy, Victoria, Australia. , (Australia)
Type
Published Article
Journal
The Laryngoscope
Publisher
Wiley (John Wiley & Sons)
Publication Date
Sep 01, 2018
Volume
128
Issue
9
Pages
2076–2083
Identifiers
DOI: 10.1002/lary.27131
PMID: 29481710
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The outcomes of unilateral radiotherapy treatment for patients with p16/HPV-positive squamous cell carcinomas of unknown primary (SCCUP) affecting cervical lymph nodes are under-reported. Compared to radiating large volumes of the pharyngeal axis (the more common approach), this is potentially a much less toxic treatment for a good prognosis group. Retrospective cohort study. We identified patients with SCCUP who were treated radically at our center and did not have parotid or isolated level IV or V nodal involvement. Failure-free and overall survivals were calculated using Kaplan-Meier methods. From 2004 to 2012, there were 49 radically treated patients with SCCUP. Fourteen patients had bilateral neck treatment (they had bilateral nodal disease or suspected lesions in the base of tongue, though not proven with biopsy), two had surgery alone, whereas 33 had unilateral radiotherapy (after neck dissection, excisional biopsy, or definitively with concurrent chemotherapy). Of the 33 patients, 21 tested positive to p16/HPV and had median follow-up of 57 months. In this group, no isolated contralateral neck failures or putative primaries emerged. There was 1/21 (4.3%) ipsilateral neck failure, 1/21 (4.3%) concurrent contralateral neck and distant failure, and 1/21 (4.3%) patient with distant failure. The 5-year freedom from failure was 78% (95% confidence interval [CI]: 56%-100%) and overall survival was 90% (95% CI: 79%-100%). With no emergence of putative primaries and no isolated contralateral neck failures, this single-institution experience in p16/HPV-positive SCCUP patients suggests that unilateral radiotherapy may be an underutilized management strategy. 4 Laryngoscope, 128:2076-2083, 2018. © 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Report this publication

Statistics

Seen <100 times